EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia

Ewelina Woźniak iD, Agnieszka Woźniak, Agnieszka Pawlos, Marlena Broncel iD, Joanna Satała, Bożena Bukowska iD, Paulina Gorzelak-Pabiś

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262110529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ewelina Woźniak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-…. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, DNA Damage, PCSK9 Inhibitors, Anticholesteremic Agents. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterozygous familial hypercholesterolemia (HeFH) is a common autosomal dominant genetic disease (1:250) characterized by elevated LDL-C. Patients with HeFH are at increased risk of premature atherosclerosis and have at least a 10-fold greater chance of cardiovascular disease (CVD). The present study examines the effect of PCSK9 inhibitor treatment (iPCSK9: arilocumab or evolocumab) on DNA damage in HeFH patients. Fifty-six patients were studied, with a normolipidemic group (control; n = 20) and patients with HeFH (study group; n = 36). DNA damage was determined by alkaline comet assay and PCSK9 protein level by ELISA. PCSK9i treatment was found to be associated with lower DNA damage, Lp(a), PCSK9, and lipid profile compared to before treatment. However, 16 of 36 patients still had Lp(a) values above 125 nmol/L, and reduced Lp(a) did not correlate with reduced DNA damage. Reduced PCSK9 demonstrated a moderately positive correlation (r = 0.48) with reduced DNA damage. PCSK9i therapy reduces the level of DNA damage in HeFH patients, regardless of the type of inhibitor. While our findings confirm that PCSK9 treatment can reduce DNA damage, the mechanism remains unclear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IIDNA DamagePCSK9 InhibitorsAnticholesteremic AgentsHumansMaleFemaleMiddle AgedAdultProprotein Convertase 9HeterozygoteAntibodies, Monoclonal, HumanizedCholesterol, LDL

Stichwörter der Autor:innen

DNA damagePCSK9 inhibitorsheterozygous familial hypercholesterolemia

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9evolocumabAntibodies, Monoclonal, HumanizedCholesterol, LDLAnticholesteremic Agents

Autor:innen und Institutionen

  • Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-347 Lodz, Poland.
  • Department of Biophysics of Environmental Pollution, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.

ORCID-Profile: Ewelina Woźniak, Marlena Broncel, Bożena Bukowska

Förderung

  • National Science Center

Zitieren

APA

Woźniak, E., Woźniak, A., Pawlos, A., Broncel, M., Satała, J., Bukowska, B., & Gorzelak-Pabiś, P. (2025). Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110529

Vancouver

Woźniak E, Woźniak A, Pawlos A, Broncel M, Satała J, Bukowska B, et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262110529

BibTeX
@article{Woniak2025,
  author = {Woźniak, Ewelina and Woźniak, Agnieszka and Pawlos, Agnieszka and Broncel, Marlena and Satała, Joanna and Bukowska, Bożena and Gorzelak-Pabiś, Paulina},
  title = {Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262110529}
}
Kostenlos starten →